The Sabin Vaccine Institute announced it has provided 700 of its Marburg Virus Disease (MVD) vaccine candidates (PHV01) to the Republic of Rwanda to support the ongoing disease outbreak response.
As of October 5, 2024, the initial vaccine shipment will be used in a trial targeting frontline workers in Rwanda, including healthcare professionals.
Pending a request from Rwandan officials and authorization from others, Sabin plans to supply additional vaccines.
Read More
